NCT03106324 2025-11-24
A Safety Study of Lenalidomide in Previously Untreated Adult Multiple Myeloma Patients Who Are Not Eligible for Transplant
Celgene
Active not recruiting
Clinical Trials
7 trialsNCT07206810 2025-10-03
A Study of the Bortezomib, Lenalidomide, and Dexamethasone Regimen for the Treatment of Newly Diagnosed Multiple Myeloma Patients
The First Affiliated Hospital of Soochow University
Completed
NCT06163040 2025-07-31
A Study to Evaluate the Safety of Empliciti® (Elotuzumab) When Treating Patients With Multiple Myeloma in Taiwan
Bristol-Myers Squibb
Completed
NCT05495620 2022-08-10
Long-term KRd in Relapsed and/or Refractory Multiple Myeloma
Dong-A University Hospital
Unknown
NCT01752075 2019-11-18
A Non-interventional, Observational Post-marketing Registry of Patients Treated With Revlimid (Lenalidomide) in Taiwan
Celgene
Completed
NCT02556905 2017-12-04
A Study to Collect and Evaluate the Safety and Efficacy Information of Korean Multiple Myeloma Patients Treated With REVLIMID®, After Approval of Marketing Authorization for New Drug in Korea
Celgene
Completed
NCT01947309 2017-01-12
Observational Registry Study of Chinese Patients Treated With Revlimid (Lenalidomide)
Celgene
Terminated